Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
37.24 USD | -5.02% | -5.40% | -26.19% |
05:17pm | Ionis Pharmaceuticals Says Potential Angelman Syndrome Therapy Improves Symptoms in Phase 1/2a Study | MT |
04:38pm | Stocks in motion: Walmart, Chubb, Deere... |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.19% | 5.72B | |
+31.53% | 49.46B | |
+1.76% | 42.58B | |
+48.83% | 42.49B | |
-5.26% | 29.09B | |
+12.89% | 26.61B | |
-23.59% | 18.64B | |
+7.74% | 13.16B | |
+31.00% | 12.55B | |
+24.05% | 12.1B |
- Stock Market
- Equities
- IONS Stock
- News Ionis Pharmaceuticals, Inc.
- Barclays Adjusts Ionis Pharmaceuticals Price Target to $40 From $44, Maintains Equal Weight Rating